Thursday October 29, 2020

Irish-based Amryt Pharma gets boost for drug in France

Ian Guider

Markets Editor

21st October, 2018

Irish-based drug company Amryt Pharma has said its flagship treatment will now be reimbursed by health authorities in France.

The approval for reimbursement will mean that the drug, Lojuxta, which treats a rare condition that can lead to heart attacks, is now available in five key European countries including Britain, Italy, Germany and Spain.

Analysts at Stifel, which is broker to Amryt, estimate that about 100 people in France have homozygous familial hypercholesterolaemia with about...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Related Stories

The state’s National Cyber Security Centre is constantly dealing with suspected attacks and urgently needs more resources

Michael Brennan | 1 month ago

We are far less reliant on the UK as a trading partner now than in previous decades — our focus needs to switch to the many challenges and opportunities of the future

Neale Richmond | 1 month ago

Covid-19 and an economic crisis are exacerbating the trauma of this month’s explosion, writes a Concern worker on the ground

Dom Hunt | 2 months ago